Metabolic syndrome and its components such as obesity, hypertriglyceridemia, type-2 diabetes mellitus (DM-T2), and arterial hypertension are unequivocally serious problems for every society. This is especially true in economically developed countries where the imbalance in lifestyle between caloric intake and caloric output still gets greater and greater. This fact is not only a concern for the adult population but for children as well. However, metabolic syndrome does not only affect society and health in regards to cardiovascular diseases, it significantly concerns gastroenterology where it is classified as nonalcoholic fatty pancreas disease (NAFPD). The data gained from several trials show that the prevalence of NAFDP is 33% (95% CI 24–41%). When it comes to the diagnostic procedures concerning the presence of pancreatic fat, a whole spectrum of suitable methods are recommended. Probably, the most exact method is the use of magnetic resonance imaging. However, for common clinical practice, the abdominal sonographic examination based on the comparison of the pancreatic parenchymatous echogenity versus renal or hepatic echogenity is used. The clinical consequences of pancreatic steatosis and steatopancreatitis are significant. These diseases are connected with DM-T2 and insulin resistance. In recent years, changes of exocrine pancreatic function, particularly its decrease, have also been described. It is known that there is a close correlation between NAFPD and nonalcoholic hepatic steatosis and also with the increased thickness of aortic intima-media. There is also an important relationship between NAFPD and pancreatic carcinoma. Pancreatic steatosis, and especially its NAFPD form, is a serious state which can be treatable by the possible effective management of metabolic syndrome parameters, including obesity.

1.
Ogilvie R. The island of Langerhans in 19 cases of obesity.
J Pathol
. 1933;37(3):473–81.
2.
Olsen TS. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight.
Acta Pathol Microbiol Scand A
. 1978 Sep;86A(5):367–73.
3.
Stamm BH. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease.
Hum Pathol
. 1984 Jul;15(7):677–83.
4.
van Geenen EJ, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease.
Pancreas
. 2010 Nov;39(8):1185–90.
5.
Pezzilli R, Calculli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus?
World J Diabetes
. 2014 Aug 15;5(4):415–9.
6.
Smits MM, van Geenen EJ. The clinical significance of pancreatic steatosis.
Nat Rev Gastroenterol Hepatol
. 2011 Mar;8(3):169–77.
7.
Tariq H, Nayudu S, Akella S, Glandt M, Chilimuri S. Non-alcoholic fatty pancreatic disease: A review of Literature.
Gastroenterol Res
. 2016 Dec;9(6):87–91.
8.
Wang CY, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population.
J Am Heart Assoc
. 2014 Feb;3(1):e000297.
9.
Lesmana CR, Pakasi LS, Inggriani S, Aidawati ML, Lesmana LA. Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study.
BMC Gastroenterol
. 2015 Dec;15(1):174.
10.
Zhou J, Li ML, Zhang DD, Lin HY, Dai XH, Sun XL, et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population.
Pancreatology
. 2016 Jul-Aug;16(4):578–83.
11.
Pham YH, Bingham BA, Bell CS, Greenfield SA, John SD, Robinson LH, et al. Prevalence of pancreatic steatosis at a pediatric tertiary care center.
South Med J
. 2016 Mar;109(3):196–8.
12.
Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet.
J Clin Biochem Nutr
. 2010 May;46(3):212–23.
13.
Heni M, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study.
Diabetes Metab Res Rev
. 2010 Mar;26(3):200–5.
14.
Rossi AP, Fantin F, Zamboni GA, Mazzali G, Rinaldi CA, Del Giglio M, et al. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women.
Obesity (Silver Spring)
. 2011 Sep;19(9):1747–54.
15.
Carter R, Mouralidarane A, Soeda J, Ray S, Pombo J, Saraswati R, et al. Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms.
PLoS One
. 2014 Mar;9(3):e89505
16.
Bojkova M, Dite P, Kunovsky L, Blaho M, -Kianicka B, Novotny I, et al. The role of -metabolic syndrome in induction of chronic pancreatitis after the first attack of acute pancreatitis – multicentric study. (In Press), Digestive Diseases.
17.
Gaborit B, Abdesselam I, Kober F, Jacquier A, Ronsin O, Emungania O, et al. Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss.
Int J Obes
. 2015 Mar;39(3):480–7.
18.
Jeong HT, Lee MS, Kim MJ. Quantitative analysis of pancreatic echogenicity on transabdominal sonography: correlations with metabolic syndrome.
J Clin Ultrasound
. 2015 Feb;43(2):98–108.
19.
Sepe PS, Ohri A, Sanaka S, Berzin TM, Sekhon S, Bennett G, et al. A prospective evaluation of fatty pancreas by using EUS.
Gastrointest Endosc
. 2011 May;73(5):987–93.
20.
Choi CW, Kim GH, Kang DH, Kim HW, Kim DU, Heo J, et al. Associated factors for a hyperechogenic pancreas on endoscopic ultrasound.
World J Gastroenterol
. 2010 Sep;16(34):4329–34.
21.
Ustundag Y, Ceylan G, Hekimoglu K. Pancreatic hyperechogenicity on endoscopic ultrasound examination.
World J Gastroenterol
. 2011 Apr;17(15):2061–2.
22.
Catanzaro R, Cuffari B, Italia A, Marotta F. Exploring the metabolic syndrome: nonalcoholic fatty pancreas disease.
World J Gastroenterol
. 2016 Sep;22(34):7660–75.
23.
Kim SY, Kim H, Cho JY, Lim S, Cha K, Lee KH, et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications.
Radiology
. 2014 Apr;271(1):104–12.
24.
Lee JS, Kim SH, Jun DW, Han JH, Jang EC, Park JY, et al. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome.
World J Gastroenterol
. 2009 Apr;15(15):1869–75.
25.
Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes.
Clin Anat
. 2007 Nov;20(8):933–42.
26.
Hannukainen JC, Borra R, Linderborg K, Kallio H, Kiss J, Lepomäki V, et al. Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity.
J Hepatol
. 2011 Mar;54(3):545–52.
27.
Yu H, Shimakawa A, McKenzie CA, Brodsky E, Brittain JH, Reeder SB. Multiecho water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling.
Magn Reson Med
. 2008 Nov;60(5):1122–34.
28.
Yokoo T, Shiehmorteza M, Hamilton G, Wolfson T, Schroeder ME, Middleton MS, et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T.
Radiology
. 2011 Mar;258(3):749–59.
29.
Popescu A, Săftoiu A. Can elastography replace fine needle aspiration?
Endosc Ultrasound
. 2014 Apr;3(2):109–17.
30.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
Circulation
. 2009 Oct;120(16):1640–5.
31.
Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk.
J Am Coll Cardiol
. 2002 Sep;40(5):937–43.
32.
Côté M, Mauriège P, Bergeron J, Alméras N, Tremblay A, Lemieux I, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men.
J Clin Endocrinol Metab
. 2005 Mar;90(3):1434–9.
33.
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease.
Circ Res
. 2005 May;96(9):939–49.
34.
Kul S, Karadeniz A, Dursun İ, Şahin S, Faruk Çırakoğlu Ö, Raşit Sayın M, et al. el al. Non-alcoholic fatty pancreas disease is associated with increased epicardial adipose tissue and aortic intima-media thickness.
Acta Cardiol Sin
. 2019 Mar;35(2):118–25.
35.
Bi Y, Wang JL, Li ML, Zhou J, Sun XL. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis.
Diabetes Metab Res Rev
. 2019 Jul;35(5):e3142.
36.
Della Corte C, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E, et al. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat.
Clin Endocrinol (Oxf)
. 2015 Nov;83(5):656–62.
37.
Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, et al. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging.
Am J Gastroenterol
. 2014 Apr;109(4):589–97.
38.
Lê KA, Ventura EE, Fisher JQ, Davis JN, Weigensberg MJ, Punyanitya M, et al. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers.
Diabetes Care
. 2011 Feb;34(2):485–90.
39.
Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.
Diabetes Care
. 1994 Sep;17(9):961–9.
40.
Ou HY, Wang CY, Yang YC, Chen MF, Chang CJ. The association between nonalcoholic fatty pancreas disease and diabetes.
PLoS One
. 2013 May;8(5):e62561.
41.
Yu TY, Wang CY. Impact of non-alcoholic fatty pancreas disease on glucose metabolism.
J Diabetes Investig
. 2017 Nov;8(6):735–47.
42.
Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes.
Diabetes Care
. 2007 Nov;30(11):2916–21.
43.
van der Zijl NJ, Goossens GH, Moors CC, van Raalte DH, Muskiet MH, Pouwels PJ, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism.
J Clin Endocrinol Metab
. 2011 Feb;96(2):459–67.
44.
Stolzenberg-Solomon RZ, Adams K, Leitzmann M, Schairer C, Michaud DS, Hollenbeck A, et al. Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort.
Am J Epidemiol
. 2008 Mar;167(5):586–97.
45.
Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer.
JAMA
. 2001 Aug;286(8):921–9.
46.
Tomita Y, Azuma K, Nonaka Y, Kamada Y, Tomoeda M, Kishida M, et al. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma.
Pancreas
. 2014 Oct;43(7):1032–41.
47.
Lesmana CR, Gani RA, Lesmana LA. Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: A single-center experience.
JGH Open
. 2017 Dec;2(1):4–7.
48.
Tranchart H, Gaujoux S, Rebours V, Vullierme MP, Dokmak S, Levy P, et al. Preoperative CT scan helps to predict the occurrence of severe pancreatic fistula after pancreaticoduodenectomy.
Ann Surg
. 2012 Jul;256(1):139–45.
49.
Gaujoux S, Torres J, Olson S, Winston C, Gonen M, Brennan MF, et al. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Ann Surg Oncol
. 2012 Sep;19(9):2908–16.
50.
Prachayakul V, Aswakul P. Pancreatic Steatosis: What Should Gastroenterologists Know? JOP.
J Pancreas (Online)
. 2015;16(3):227–31.
51.
Miyake H, Sakagami J, Yasuda H, Sogame Y, Kato R, Suwa K, et al. Association of fatty pancreas with pancreatic endocrine and exocrine function.
PLoS One
. 2018 Dec;13(12):e0209448.
52.
Pezzilli R, Andriulli A, Bassi C, Balzano G, Cantore M, Delle Fave G, et al.; Exocrine Pancreatic Insufficiency collaborative (EPIc) Group. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas.
World J Gastroenterol
. 2013 Nov;19(44):7930–46.
53.
Tahtacı M, Algın O, Karakan T, Yürekli ÖT, Alışık M, Köseoğlu H, et al. Can pancreatic steatosis affect exocrine functions of pancreas?
Turk J Gastroenterol
. 2018 Sep;29(5):588–94.
54.
d’Assignies G, Ruel M, Khiat A, Lepanto L, Chagnon M, Kauffmann C, et al. Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods.
Eur Radiol
. 2009 Aug;19(8):2033–40.
55.
Mishra AK, Dubey V, Ghosh AR. Obesity: an overview of possible role(s) of gut hormones, lipid sensing and gut microbiota.
Metabolism
. 2016 Jan;65(1):48–65.
56.
Acharya C, Cline RA, Jaligama D, Noel P, Delany JP, Bae K, et al. Fibrosis reduces severity of acute-on-chronic pancreatitis in humans.
Gastroenterology
. 2013 Aug;145(2):466–75.
57.
van Geenen EJ, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ. Smoking is related to pancreatic fibrosis in humans.
Am J Gastroenterol
. 2011 Jun;106(6):1161–6.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.